Thiogenesis Therapeutics, Corp.
Loading stock data...
Stock Performance
Price History
-
Drag to select time range
-
Market Data
Market Cap
27.0M
P/E Ratio
-
52-Week High
-
52-Week Low
-
Avg Volume
-
Beta
-
Forward P/E
-
Dividend Yield
-
EV/Revenue
-
Price/Book
-
Business Overview
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome. The company is headquartered in Toronto, Canada.
Healthcare
Biotechnology
TSXV
Key Financial Metrics
-
Revenue
-3.1M
Net Income
C$-0.07
EPS (Diluted)
-3.9M
Free Cash Flow
Profitability
Gross Margin
-
Operating Margin
-
Net Profit Margin
-
EBITDA
-3.6M
Returns & Efficiency
Return on Assets (ROA)
-79.0%
Return on Equity (ROE)
-91.8%
Dividend Yield
-
Payout Ratio
-
Financial Health
Total Assets
4.0M
Total Debt
-
Debt to Equity
-
Current Ratio
7.14
Company Info
| Industry | Biotechnology |
| HQ | Toronto, Canada |
| Fiscal Year End | 1735603200 |
| Currency | CAD |
| Website | www.thiogenesis.com |
Peers
Bausch + Lomb Corporation
BLCO.TO
7.9B
P/E: --
Bausch Health Companies Inc.
BHC.TO
2.5B
P/E: 12.0
Extendicare Inc.
EXE.TO
2.5B
P/E: 23.7
Sienna Senior Living Inc.
SIA.TO
2.2B
P/E: 53.2
Cronos Group Inc.
CRON.TO
1.4B
P/E: 24.1
Tilray Brands, Inc.
TLRY.TO
1.2B
P/E: --
WELL Health Technologies Corp.
WELL.TO
1.1B
P/E: --
Knight Therapeutics Inc.
GUD.TO
631.8M
P/E: --
Insider Activity
Sentiment
Bullish
Shares Bought
64,000
Shares Sold
0
Total Transactions
1
SEDAR+ Filings
View All Filings3
Annual Reports
18
Quarterly Reports
22
MD&A
39
News Releases
5
Material Changes
2
Prospectuses
10
Governance
45
Certifications
50
Other
●
2023-05-01
●
2021-06-14
●
2020-06-22
●
2025-08-07
●
2023-12-20
●
2021-03-16
●
2020-11-04
●
2019-07-16
●
2019-05-27
●
2019-04-03
Interactive Charts
Company Profile
General Information
| Company Name | Thiogenesis Therapeutics, Corp. |
| Ticker | TTI.V |
| Exchange | TSXV |
| Sector | Healthcare |
| Industry | Biotechnology |
| Headquarters | Toronto, Canada |
| Fiscal Year End | 1735603200 |
| Currency | CAD |
| Website | www.thiogenesis.com |
Financial Summary
| Market Cap | 27.0M |
| Revenue | N/A |
| Net Income | -3.1M |
| P/E Ratio | N/A |
| EPS (Diluted) | C$-0.07 |
| Net Margin | N/A |
| ROE | -91.8% |
| Dividend Yield | N/A |
Business Description
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome. The company is headquartered in Toronto, Canada.